サンプル依頼リスト カート
  • English
  • Korean
表紙：急性呼吸窮迫症候群（ARDS）の世界市場レポート 2024年
市場調査レポート
商品コード
1415752

急性呼吸窮迫症候群（ARDS）の世界市場レポート 2024年

Acute Respiratory Distress Syndrome (ARDS) Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.97円
急性呼吸窮迫症候群（ARDS）の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

急性呼吸窮迫症候群（ARDS）の市場規模は近年急速に拡大しています。2023年の11億7,000万米ドルから2024年には12億9,000万米ドルに、CAGR10.6％で拡大します。実績期間の成長は、クリティカルケア医学の進歩、高齢化、肺リハビリテーション、集学的ケアチームに起因しています。

急性呼吸窮迫症候群（ARDS）の市場規模は今後数年で急成長が見込まれます。2028年にはCAGR10.7％で19億3,000万米ドルに成長します。予測期間の成長は、世界のヘルスケアへの備え、ワクチン開発と感染症管理、遠隔医療と遠隔モニタリング、患者中心のケアモデルに起因しています。予測期間の主な動向には、人工肺装置、個別化された換気戦略、肺保護換気、dsサブタイプに対する薬物療法などが含まれます。

急性呼吸窮迫症候群（ARDS）市場の拡大予測は、肺炎の有病率の増加に直接関連しています。肺炎は、片方または両方の肺を侵す感染性疾患で、肺の気嚢（肺胞）に液体や膿が蓄積します。肺炎は肺内で炎症反応を引き起こし、血管透過性の亢進と肺胞への体液漏出を引き起こします。この体液の蓄積は酸素と二酸化炭素の交換を妨げ、呼吸困難を引き起こします。2021年の米国疾病予防管理センターのデータによると、米国における肺炎による死亡者数は41,309人で、人口10万人当たりの死亡率は12.4人でした。このように、肺炎の有病率の上昇は、急性呼吸窮迫症候群（ARDS）市場の成長の原動力となっています。

呼吸器疾患の増加傾向は、急性呼吸窮迫症候群（ARDS）市場の拡大に大きく貢献します。呼吸器疾患には、気道や肺を含む呼吸器系に影響を及ぼすさまざまな病状が含まれ、しばしば呼吸困難を引き起こします。特に、COVID-19のような症例に代表される呼吸器疾患の急増は、ARDS市場成長の主な触媒として際立っています。呼吸器疾患の有病率が上昇し続けるにつれて、ARDS治療薬や療法に対する需要も急増し、結果として市場の成長が促進されます。その一例として、チリ保健省が2021年3月に発表した報告書によると、チリでは呼吸器疾患が死亡率の大きな割合を占めており、インフルエンザおよび肺炎の47%、慢性下気道障害の3%、間質性呼吸器疾患の3%を占めています。さらに、その他の呼吸器疾患は全症例の5％を占めています。従って、呼吸器疾患の発生率の増加が急性呼吸窮迫症候群（ARDS）市場成長の原動力となっています。

2023年の急性呼吸窮迫症候群（ARDS）市場で最大の地域は北米でした。急性呼吸窮迫症候群（ARDS）レポートがカバーしている地域は、アジア太平洋、西欧、中東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の急性呼吸窮迫症候群（ARDS）市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 診断
  • 処理
  • 世界の急性呼吸窮迫症候群（ARDS）市場、原因別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 2019年コロナウイルス感染症（COVID-19）
  • 敗血症
  • 有害物質の吸入
  • 重度の肺炎
  • その他の原因
  • 世界の急性呼吸窮迫症候群（ARDS）市場、重症度別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 軽症
  • 中症
  • 重症
  • 世界の急性呼吸窮迫症候群（ARDS）市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院
  • クリニック
  • 外来サービスセンター
  • その他のエンドユーザー

第7章 地域および国の分析

  • 世界の急性呼吸窮迫症候群（ARDS）市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の急性呼吸窮迫症候群（ARDS）市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 急性呼吸窮迫症候群（ARDS）市場の競合情勢
  • 急性呼吸窮迫症候群（ARDS）市場企業プロファイル
    • Johnson &Johnson Services Inc.
    • Novartis AG
    • GlaxoSmithKline plc
    • Medtronic plc
    • Boehringer Ingelheim International GmbH

第31章 その他の主要および革新的な企業

  • Gilead Sciences Inc.
  • Amgen Inc.
  • Fresenius SE & Co. KGaA
  • Koninklijke Philips N.V.
  • Baxter International Inc.
  • Teva Pharmaceutical Industries Ltd.
  • CSL Behring
  • Terumo Corporation
  • ResMed Inc.
  • Smiths Medical Inc.
  • Drager Safety AG & Co. KGaA.
  • Getinge AB
  • Mallinckrodt plc
  • Masimo Corporation
  • United Therapeutics Corporation

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r12351

“Acute Respiratory Distress Syndrome (ARDS) Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on acute respiratory distress syndrome (ards) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for acute respiratory distress syndrome (ards)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The acute respiratory distress syndrome (ards) market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Type: Diagnosis; Treatment
  • 2) By Cause: COVID-19 Disease 2019 (COVID-19); Sepsis; Inhalation Of Harmful Substances; Severe Pneumonia; Other Causes
  • 3) By Severity: Mild; Moderate; Severe
  • 4) By End User: Hospitals; Clinics; Ambulatory Service Centers; Other End Users
  • Companies Mentioned: Johnson & Johnson Services Inc.; Novartis AG; GlaxoSmithKline plc; Medtronic plc; Boehringer Ingelheim International GmbH
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Acute Respiratory Distress Syndrome (ARDS) is a potentially life-threatening condition characterized by rigid, non-compliant lungs and inadequate oxygenation. This condition presents as an acute, widespread inflammatory lung injury that can affect critically ill patients. The primary approach to treating ARDS involves employing mechanical ventilation with low tidal volumes and positive end-expiratory pressure (PEEP) to support oxygen levels and minimize further lung damage.

The key facets of dealing with Acute Respiratory Distress Syndrome (ARDS) pertain to its diagnosis and treatment. Diagnosis encompasses the process of distinguishing this condition from other potential disorders and delineating its characteristics. The diagnosis of ARDS typically relies on a physical examination, chest X-ray, and oxygenation levels. ARDS can be triggered by various factors such as COVID-19 (COVID-19 Disease 2019), sepsis, exposure to harmful substances, severe pneumonia, among others, with its severity ranging from mild to moderate and severe. The primary recipients of ARDS-related services include hospitals, clinics, ambulatory service centers, and other healthcare facilities.

The acute respiratory distress syndrome (ARDS) market research report is one of a series of new reports from The Business Research Company that provides acute respiratory distress syndrome (ARDS) market statistics, including acute respiratory distress syndrome (ARDS) industry global market size, regional shares, competitors with an acute respiratory distress syndrome (ARDS) market share, detailed acute respiratory distress syndrome (ARDS) market segments, market trends and opportunities and any further data you may need to thrive in the acute respiratory distress syndrome (ARDS) industry. This acute respiratory distress syndrome (ARDS) market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The acute respiratory distress syndrome (ards) market size has grown rapidly in recent years. It will grow from $1.17 billion in 2023 to $1.29 billion in 2024 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to advancements in critical care medicine, aging population, pulmonary rehabilitation, multidisciplinary care teams.

The acute respiratory distress syndrome (ards) market size is expected to see rapid growth in the next few years. It will grow to $1.93 billion in 2028 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to global healthcare preparedness, vaccine development and infectious disease management, telemedicine and remote monitoring, patient-centered care models. Major trends in the forecast period include artificial lung devices, personalized ventilation strategies, lung protective ventilation, drug therapies for ards subtypes.

The projected expansion of the acute respiratory distress syndrome (ARDS) market is directly linked to the increasing prevalence of pneumonia. Pneumonia, an infectious condition affecting one or both lungs, results in the accumulation of fluid or pus in the air sacs (alveoli) of the lungs. Pneumonia triggers an inflammatory response within the lungs, leading to heightened blood vessel permeability and the leakage of fluid into the alveoli. This accumulation of fluid disrupts the exchange of oxygen and carbon dioxide, causing respiratory distress. To illustrate, data from the Centers for Disease Control and Prevention in 2021 revealed that pneumonia accounted for 41,309 deaths in the United States, with a mortality rate of 12.4 deaths per 100,000 population. Thus, the escalating prevalence of pneumonia serves as a driving force for the growth of the acute respiratory distress syndrome (ARDS) market.

The upward trajectory in the number of respiratory illnesses is poised to contribute significantly to the expansion of the acute respiratory distress syndrome (ARDS) market. Respiratory illnesses encompass a range of medical conditions affecting the respiratory system, including the airways and lungs, often resulting in breathing difficulties. Notably, the surge in respiratory illnesses, exemplified by cases like COVID-19, stands out as a primary catalyst for the growth of the ARDS market. As the prevalence of respiratory illnesses continues to rise, there is a corresponding surge in demand for ARDS treatments and therapies, consequently fostering market growth. As a case in point, a March 2021 report from the Ministry of Health in Chile highlighted that respiratory diseases account for a significant percentage of mortality in Chile, constituting 47% of influenza and pneumonia cases, 3% of chronic lower respiratory tract disorders, and 3% of interstitial respiratory diseases. Additionally, other respiratory ailments make up 5% of all cases. Consequently, the mounting incidence of respiratory illnesses is a driving force behind the growth of the acute respiratory distress syndrome (ARDS) market.

The growth of the acute respiratory distress syndrome (ARDS) market is anticipated to face obstacles due to the considerable expense associated with treatment. The cost of ARDS treatment can be prohibitive, potentially limiting its accessibility to certain patients. This cost encompasses inpatient expenditures, daily ICU costs, and post-hospitalization expenses. As an illustration, in March 2022, the National Library of Medicine reported that mean inpatient ARDS costs in the United States varied from $8,476 to $547,974. Consequently, the elevated cost of treatment serves as a deterrent to the expansion of the acute respiratory distress syndrome (ARDS) market.

Prominent companies operating within the acute respiratory distress syndrome (ARDS) market are dedicating their efforts to the creation of groundbreaking drugs and supplements, including Aviptadil and HSP90 inhibitors, aimed at reinforcing their market position. Aviptadil, a synthetic vasoactive intestinal peptide (VIP), is designed to specifically target receptors on lung alveolar type II cells. For instance, in November 2022, Zuventus Healthcare Ltd., an Indian pharmaceutical manufacturing company, introduced Aviptadil as a treatment for acute respiratory distress syndrome. Aviptadil, functioning as a vasoactive intestinal peptide supplement, enhances breathing and reduces mortality in ARDS patients. This is achieved through Aviptadil's capacity to safeguard and regenerate Type-2 Pneumocytes, restore Type-1 Pneumocytes, increase surfactant synthesis, and suppress interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha).

In January 2022, AcelRx Pharmaceuticals Inc., a specialized pharmaceutical company based in the United States, acquired Lowell Therapeutics Inc. for $32.5 million. This strategic acquisition empowers AcelRx Pharmaceuticals to expand its product portfolio and solidify its standing in the pharmaceutical industry. Lowell Therapeutics Inc., also based in the U.S., is a pharmaceutical company dedicated to developing products for the treatment of acute respiratory distress syndrome (ARDS) and disseminated intravascular coagulation (DIC).

Major players in the acute respiratory distress syndrome (ards) market are Johnson & Johnson Services Inc., Novartis AG, GlaxoSmithKline PLC, Medtronic PLC, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., Fresenius SE & Co. KGaA, Koninklijke Philips N.V., Baxter International Inc., Teva Pharmaceutical Industries Ltd., CSL Behring, Terumo Corporation, ResMed Inc., Smiths Medical Inc., Drager Safety AG & Co. KGaA., Getinge AB, Mallinckrodt PLC, Masimo Corporation, United Therapeutics Corporation, Fisher & Paykel Healthcare Corporation Limited, Hamilton Medical AG, Zuventus Healthcare Ltd., Windtree Therapeutics Inc., Faron Pharmaceuticals Oy, AcelRx Pharmaceuticals Inc.

North America was the largest region in the acute respiratory distress syndrome (ARDS) market in 2023. The regions covered in acute respiratory distress syndrome (ARDS) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the acute respiratory distress syndrome (ARDS) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The acute respiratory distress syndrome (ARDS) market includes revenues earned by entities by providing resolution and recovery services, medication, supplemental oxygen and mechanical ventilation. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute respiratory distress syndrome (ARDS) market consists of sales of neuromuscular blockers, corticosteroids, monitoring devices, diagnostic devices and therapeutic devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Acute Respiratory Distress Syndrome (ARDS) Market Characteristics

3. Acute Respiratory Distress Syndrome (ARDS) Market Trends And Strategies

4. Acute Respiratory Distress Syndrome (ARDS) Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Acute Respiratory Distress Syndrome (ARDS) Market Size and Growth

  • 5.1. Global Acute Respiratory Distress Syndrome (ARDS) Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Acute Respiratory Distress Syndrome (ARDS) Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Acute Respiratory Distress Syndrome (ARDS) Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Acute Respiratory Distress Syndrome (ARDS) Market Segmentation

  • 6.1. Global Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Diagnosis
  • Treatment
  • 6.2. Global Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Coronavirus Disease 2019 (COVID-19)
  • Sepsis
  • Inhalation Of Harmful Substances
  • Severe Pneumonia
  • Other Causes
  • 6.3. Global Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Mild
  • Moderate
  • Severe
  • 6.4. Global Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Clinics
  • Ambulatory Service Centers
  • Other End Users

7. Acute Respiratory Distress Syndrome (ARDS) Market Regional And Country Analysis

  • 7.1. Global Acute Respiratory Distress Syndrome (ARDS) Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Acute Respiratory Distress Syndrome (ARDS) Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) Market

  • 8.1. Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Acute Respiratory Distress Syndrome (ARDS) Market

  • 9.1. China Acute Respiratory Distress Syndrome (ARDS) Market Overview
  • 9.2. China Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Acute Respiratory Distress Syndrome (ARDS) Market

  • 10.1. India Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Acute Respiratory Distress Syndrome (ARDS) Market

  • 11.1. Japan Acute Respiratory Distress Syndrome (ARDS) Market Overview
  • 11.2. Japan Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Acute Respiratory Distress Syndrome (ARDS) Market

  • 12.1. Australia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Acute Respiratory Distress Syndrome (ARDS) Market

  • 13.1. Indonesia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Acute Respiratory Distress Syndrome (ARDS) Market

  • 14.1. South Korea Acute Respiratory Distress Syndrome (ARDS) Market Overview
  • 14.2. South Korea Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Acute Respiratory Distress Syndrome (ARDS) Market

  • 15.1. Western Europe Acute Respiratory Distress Syndrome (ARDS) Market Overview
  • 15.2. Western Europe Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Acute Respiratory Distress Syndrome (ARDS) Market

  • 16.1. UK Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Acute Respiratory Distress Syndrome (ARDS) Market

  • 17.1. Germany Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Acute Respiratory Distress Syndrome (ARDS) Market

  • 18.1. France Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Acute Respiratory Distress Syndrome (ARDS) Market

  • 19.1. Italy Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Acute Respiratory Distress Syndrome (ARDS) Market

  • 20.1. Spain Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Acute Respiratory Distress Syndrome (ARDS) Market

  • 21.1. Eastern Europe Acute Respiratory Distress Syndrome (ARDS) Market Overview
  • 21.2. Eastern Europe Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Acute Respiratory Distress Syndrome (ARDS) Market

  • 22.1. Russia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Acute Respiratory Distress Syndrome (ARDS) Market

  • 23.1. North America Acute Respiratory Distress Syndrome (ARDS) Market Overview
  • 23.2. North America Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Acute Respiratory Distress Syndrome (ARDS) Market

  • 24.1. USA Acute Respiratory Distress Syndrome (ARDS) Market Overview
  • 24.2. USA Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Acute Respiratory Distress Syndrome (ARDS) Market

  • 25.1. Canada Acute Respiratory Distress Syndrome (ARDS) Market Overview
  • 25.2. Canada Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Acute Respiratory Distress Syndrome (ARDS) Market

  • 26.1. South America Acute Respiratory Distress Syndrome (ARDS) Market Overview
  • 26.2. South America Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Acute Respiratory Distress Syndrome (ARDS) Market

  • 27.1. Brazil Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Acute Respiratory Distress Syndrome (ARDS) Market

  • 28.1. Middle East Acute Respiratory Distress Syndrome (ARDS) Market Overview
  • 28.2. Middle East Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Acute Respiratory Distress Syndrome (ARDS) Market

  • 29.1. Africa Acute Respiratory Distress Syndrome (ARDS) Market Overview
  • 29.2. Africa Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Acute Respiratory Distress Syndrome (ARDS) Market Competitive Landscape And Company Profiles

  • 30.1. Acute Respiratory Distress Syndrome (ARDS) Market Competitive Landscape
  • 30.2. Acute Respiratory Distress Syndrome (ARDS) Market Company Profiles
    • 30.2.1. Johnson & Johnson Services Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Novartis AG
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. GlaxoSmithKline plc
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Medtronic plc
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Boehringer Ingelheim International GmbH
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Acute Respiratory Distress Syndrome (ARDS) Market Other Major And Innovative Companies

  • 31.1. Gilead Sciences Inc.
  • 31.2. Amgen Inc.
  • 31.3. Fresenius SE & Co. KGaA
  • 31.4. Koninklijke Philips N.V.
  • 31.5. Baxter International Inc.
  • 31.6. Teva Pharmaceutical Industries Ltd.
  • 31.7. CSL Behring
  • 31.8. Terumo Corporation
  • 31.9. ResMed Inc.
  • 31.10. Smiths Medical Inc.
  • 31.11. Drager Safety AG & Co. KGaA.
  • 31.12. Getinge AB
  • 31.13. Mallinckrodt plc
  • 31.14. Masimo Corporation
  • 31.15. United Therapeutics Corporation

32. Global Acute Respiratory Distress Syndrome (ARDS) Market Competitive Benchmarking

33. Global Acute Respiratory Distress Syndrome (ARDS) Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Acute Respiratory Distress Syndrome (ARDS) Market

35. Acute Respiratory Distress Syndrome (ARDS) Market Future Outlook and Potential Analysis

  • 35.1 Acute Respiratory Distress Syndrome (ARDS) Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Acute Respiratory Distress Syndrome (ARDS) Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Acute Respiratory Distress Syndrome (ARDS) Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer